272 related articles for article (PubMed ID: 20152041)
1. Using qualitative methods to inform the trade-off between content validity and consistency in utility assessment: the example of type 2 diabetes and Alzheimer's disease.
McGrath C; Rofail D; Gargon E; Abetz L
Health Qual Life Outcomes; 2010 Feb; 8():23. PubMed ID: 20152041
[TBL] [Abstract][Full Text] [Related]
2. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I; Coast J; Brown J
Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
[TBL] [Abstract][Full Text] [Related]
3. Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated?
Ungar WJ
Pharmacoeconomics; 2011 Aug; 29(8):641-52. PubMed ID: 21604821
[TBL] [Abstract][Full Text] [Related]
4. Health state values for use in the economic evaluation of treatments for Alzheimer's disease.
Shearer J; Green C; Ritchie CW; Zajicek JP
Drugs Aging; 2012 Jan; 29(1):31-43. PubMed ID: 22191721
[TBL] [Abstract][Full Text] [Related]
5. Accounts from developers of generic health state utility instruments explain why they produce different QALYs: A qualitative study.
Pickles K; Lancsar E; Seymour J; Parkin D; Donaldson C; Carter SM
Soc Sci Med; 2019 Nov; 240():112560. PubMed ID: 31563007
[TBL] [Abstract][Full Text] [Related]
6. Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods.
Hernández Alava M; Wailoo A; Pudney S; Gray L; Manca A
Health Technol Assess; 2020 Jun; 24(34):1-68. PubMed ID: 32613941
[TBL] [Abstract][Full Text] [Related]
7. Comparing and explaining differences in the magnitude, content, and sensitivity of utilities predicted by the EQ-5D, SF-6D, HUI 3, 15D, QWB, and AQoL-8D multiattribute utility instruments.
Richardson J; Khan MA; Iezzi A; Maxwell A
Med Decis Making; 2015 Apr; 35(3):276-91. PubMed ID: 25159172
[TBL] [Abstract][Full Text] [Related]
8. A review of health utilities across conditions common in paediatric and adult populations.
Tarride JE; Burke N; Bischof M; Hopkins RB; Goeree L; Campbell K; Xie F; O'Reilly D; Goeree R
Health Qual Life Outcomes; 2010 Jan; 8():12. PubMed ID: 20105304
[TBL] [Abstract][Full Text] [Related]
9. QALY-time: experts' view on the use of the quality-adjusted LIFE year in COST-effectiveness analysis in palliative care.
Wichmann AB; Goltstein LCMJ; Obihara NJ; Berendsen MR; Van Houdenhoven M; Morrison RS; Johnston BM; Engels Y;
BMC Health Serv Res; 2020 Jul; 20(1):659. PubMed ID: 32678021
[TBL] [Abstract][Full Text] [Related]
10. Trends in the measurement of health utilities in published cost-utility analyses.
Brauer CA; Rosen AB; Greenberg D; Neumann PJ
Value Health; 2006; 9(4):213-8. PubMed ID: 16903990
[TBL] [Abstract][Full Text] [Related]
11. Health state utility instruments compared: inquiring into nonlinearity across EQ-5D-5L, SF-6D, HUI-3 and 15D.
Gamst-Klaussen T; Chen G; Lamu AN; Olsen JA
Qual Life Res; 2016 Jul; 25(7):1667-78. PubMed ID: 26687615
[TBL] [Abstract][Full Text] [Related]
12. Systematic review of the impact of urinary tract infections on health-related quality of life.
Bermingham SL; Ashe JF
BJU Int; 2012 Dec; 110(11 Pt C):E830-6. PubMed ID: 22816657
[TBL] [Abstract][Full Text] [Related]
13. A conceptual map of health-related quality of life dimensions: key lessons for a new instrument.
Olsen JA; Misajon R
Qual Life Res; 2020 Mar; 29(3):733-743. PubMed ID: 31676970
[TBL] [Abstract][Full Text] [Related]
14. The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4.
Scuffham PA; Whitty JA; Mitchell A; Viney R
Pharmacoeconomics; 2008; 26(4):297-310. PubMed ID: 18370565
[TBL] [Abstract][Full Text] [Related]
15. A qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phases.
Gallop K; Kerr C; Simmons S; McIver B; Cohen EE
Qual Life Res; 2015 Feb; 24(2):325-38. PubMed ID: 25106505
[TBL] [Abstract][Full Text] [Related]
16. Health state valuation in low- and middle-income countries: a systematic review of the literature.
Kularatna S; Whitty JA; Johnson NW; Scuffham PA
Value Health; 2013; 16(6):1091-9. PubMed ID: 24041360
[TBL] [Abstract][Full Text] [Related]
17. Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis.
Adams R; Walsh C; Veale D; Bresnihan B; FitzGerald O; Barry M
Pharmacoeconomics; 2010; 28(6):477-87. PubMed ID: 20465316
[TBL] [Abstract][Full Text] [Related]
18. Measuring the Sensitivity and Construct Validity of 6 Utility Instruments in 7 Disease Areas.
Richardson J; Iezzi A; Khan MA; Chen G; Maxwell A
Med Decis Making; 2016 Feb; 36(2):147-59. PubMed ID: 26582319
[TBL] [Abstract][Full Text] [Related]
19. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis.
Marra CA; Woolcott JC; Kopec JA; Shojania K; Offer R; Brazier JE; Esdaile JM; Anis AH
Soc Sci Med; 2005 Apr; 60(7):1571-82. PubMed ID: 15652688
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
